BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 32274709)

  • 1. An Overview of the Structure, Mechanism and Specificity of Human Heparanase.
    Wu L; Davies GJ
    Adv Exp Med Biol; 2020; 1221():139-167. PubMed ID: 32274709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural characterization of human heparanase reveals insights into substrate recognition.
    Wu L; Viola CM; Brzozowski AM; Davies GJ
    Nat Struct Mol Biol; 2015 Dec; 22(12):1016-22. PubMed ID: 26575439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heparanase degrades syndecan-1 and perlecan heparan sulfate: functional implications for tumor cell invasion.
    Reiland J; Sanderson RD; Waguespack M; Barker SA; Long R; Carson DD; Marchetti D
    J Biol Chem; 2004 Feb; 279(9):8047-55. PubMed ID: 14630925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heparanase: Historical Aspects and Future Perspectives.
    Khanna M; Parish CR
    Adv Exp Med Biol; 2020; 1221():71-96. PubMed ID: 32274707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Computational analyses of the catalytic and heparin-binding sites and their interactions with glycosaminoglycans in glycoside hydrolase family 79 endo-β-D-glucuronidase (heparanase).
    Gandhi NS; Freeman C; Parish CR; Mancera RL
    Glycobiology; 2012 Jan; 22(1):35-55. PubMed ID: 21746763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unexpected new roles for heparanase in Type 1 diabetes and immune gene regulation.
    Parish CR; Freeman C; Ziolkowski AF; He YQ; Sutcliffe EL; Zafar A; Rao S; Simeonovic CJ
    Matrix Biol; 2013 Jun; 32(5):228-33. PubMed ID: 23499527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heparanase Inhibitors in Cancer Progression: Recent Advances.
    Kaur R; Deb PK; Diwan V; Saini B
    Curr Pharm Des; 2021; 27(1):43-68. PubMed ID: 33185156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycosaminoglycans affect heparanase location in CHO cell lines.
    Piva MB; Suarez ER; Melo CM; Cavalheiro RP; Nader HB; Pinhal MA
    Glycobiology; 2015 Sep; 25(9):976-83. PubMed ID: 26033936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-reducing end labeling of heparan sulfate via click chemistry and a high throughput ELISA assay for heparanase.
    Wu ZL; Huang X; Ethen CM; Tatge T; Pasek M; Zaia J
    Glycobiology; 2017 Jun; 27(6):518-524. PubMed ID: 28025251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell surface heparan sulfate released by heparanase promotes melanoma cell migration and angiogenesis.
    Roy M; Marchetti D
    J Cell Biochem; 2009 Feb; 106(2):200-9. PubMed ID: 19115257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multi-faceted substrate specificity of heparanase.
    Peterson SB; Liu J
    Matrix Biol; 2013 Jun; 32(5):223-7. PubMed ID: 23499529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heparanase and autoimmune diabetes.
    Simeonovic CJ; Ziolkowski AF; Wu Z; Choong FJ; Freeman C; Parish CR
    Front Immunol; 2013 Dec; 4():471. PubMed ID: 24421779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent data concerning heparanase: focus on fibrosis, inflammation and cancer.
    Secchi MF; Masola V; Zaza G; Lupo A; Gambaro G; Onisto M
    Biomol Concepts; 2015 Dec; 6(5-6):415-21. PubMed ID: 26552066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crosstalk between tumor cells and lymphocytes modulates heparanase expression.
    Theodoro TR; Matos LL; Cavalheiro RP; Justo GZ; Nader HB; Pinhal MAS
    J Transl Med; 2019 Mar; 17(1):103. PubMed ID: 30922347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemical toolbox to interrogate Heparanase-1 activity.
    Rabinowitz ZM; Somers J; Wang Z; Cui L
    Curr Opin Chem Biol; 2024 Mar; 80():102452. PubMed ID: 38555836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism-based heparanase inhibitors reduce cancer metastasis in vivo.
    de Boer C; Armstrong Z; Lit VAJ; Barash U; Ruijgrok G; Boyango I; Weitzenberg MM; Schröder SP; Sarris AJC; Meeuwenoord NJ; Bule P; Kayal Y; Ilan N; Codée JDC; Vlodavsky I; Overkleeft HS; Davies GJ; Wu L
    Proc Natl Acad Sci U S A; 2022 Aug; 119(31):e2203167119. PubMed ID: 35881786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1H NMR spectroscopic studies establish that heparanase is a retaining glycosidase.
    Wilson JC; Laloo AE; Singh S; Ferro V
    Biochem Biophys Res Commun; 2014 Jan; 443(1):185-8. PubMed ID: 24291708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FGF2 binding, signaling, and angiogenesis are modulated by heparanase in metastatic melanoma cells.
    Reiland J; Kempf D; Roy M; Denkins Y; Marchetti D
    Neoplasia; 2006 Jul; 8(7):596-606. PubMed ID: 16867222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Aspects of Heparanase Interaction with Heparan Sulfate, Heparin and Glycol Split Heparin.
    Elli S; Guerrini M
    Adv Exp Med Biol; 2020; 1221():169-188. PubMed ID: 32274710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pro-Angiogenic Effects of Latent Heparanase and Thrombin Receptor-Mediated Pathways-Do They Share a Common Ground in Melanoma Cells?
    Hoß SG; Grundmann M; Benkel T; Gockel L; Schwarz S; Kostenis E; Schlesinger M; Ilan N; Vlodavsky I; Bendas G
    Thromb Haemost; 2018 Oct; 118(10):1803-1814. PubMed ID: 30235481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.